Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist September 25, 2020
Millendo Completes Patient Recruitment for Pivotal Study of Livoletide in Prader-Willi Syndrome November 14, 2019
Millendo Reports Third Quarter 2019 Operating and Financial Results; Livoletide pivotal study in PWS completed recruitment and is on track to report topline results in 1H20; Nevanimibe Phase 2b study in CAH continues recruitment, topline results expected November 14, 2019
